Major deals boost CT biopharma sector after period of closings and layoffs
A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...
C&EN20h
FDA approves drug for neurofibromatosis
The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...
Managed Healthcare Executive21h
FDA Approves Gomekli, First and Only NF1-PN Treatment for Both Children and Adults
Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult ...
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...